Paroxetine

Brand names: Paxil · Active ingredient: Paroxetine Hydrochloride

In short: Paroxetine extended-release tablets are indicated in adults for the treatment of: Major depressive disorder (MDD) Panic disorder (PD) Social anxiety disorder (SAD) Premenstrual dysphoric disorder (PMDD)

Forms & strengthsParoxetine extended-release tablets are available as: 12.5 mg yellow, film-coated, round, biconvex tablets debossed with "v11" on one side. 25 mg pink, film-coated, round, biconvex tablets debossed with "v12" on one side. …
LabelWestminster Pharmaceuticals, LLC
Label updatedNov 09, 2026

What is Paroxetine used for?

Paroxetine extended-release tablets are indicated in adults for the treatment of:

Major depressive disorder (MDD)

Panic disorder (PD)

Social anxiety disorder (SAD)

Premenstrual dysphoric disorder (PMDD)

âš  Boxed warning (FDA's strongest warning)

Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors . Paroxetine extended-release tablets are not approved for use in pediatric patients .

Paroxetine dosage

Administer paroxetine extended-release tablets as a single daily dose in the morning, with or without food. Swallow tablets whole and do not chew or crush.

The recommended initial dosage and maximum dosage of paroxetine extended-release tablets in patients with MDD, PD, and SAD are presented in Table 1.

In patients with an inadequate response, dosage may be increased in increments of 12.5 mg per day at intervals of at least 1 week, depending on tolerability.

Indication | Starting Dose | Maximum Dose

MDD | 25 mg | 62.5 mg

PD | 12.5 mg | 75 mg

SAD | 12.5 mg | 37.5 mg

The recommended starting dosage in women with PMDD is 12.5 mg per day. Paroxetine extended-release tablets may be administered either continuously (every day throughout the menstrual cycle) or intermittently (only during the luteal phase of the menstrual cycle, i.e., starting the daily dosage 14 days prior to the anticipated onset of menstruation and continuing through the onset of menses). Intermittent dosing is repeated with each new cycle.

In patients with an inadequate response, the dosage may be increased to the maximum recommended dosage of 25 mg per day, depending on tolerability. Institute dosage adjustments at intervals of at least 1 week.

Prior to initiating treatment with paroxetine extended-release tablets or another antidepressant, screen patients for a personal or family history of bipolar disorder, mania, or hypomania .

The recommended initial dose of paroxetine extended-release tablets is 12.5 mg per day for elderly patients, patients with severe renal impairment, and patients with severe hepatic impairment. Reduce initial dose and increase up-titration intervals if necessary. Dosage should not exceed 50 mg per day for MDD or PD and should not exceed 37.5 mg per day for SAD .

At least 14 days must elapse between discontinuation of a monoamine oxidase inhibitor (MAOI) antidepressant and initiation of paroxetine extended-release tablets. In addition, at least 14 days must elapse after stopping paroxetine extended-release tablets before starting an MAOI antidepressant .

Adverse reactions may occur upon discontinuation of paroxetine extended-release tablets . Gradually reduce the dosage rather than stopping paroxetine extended-release tablets abruptly whenever possible.

How to take Paroxetine — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Suicidal Thoughts and Behaviors

Advise patients and caregivers to look for the emergence of suicidality, especially early during treatment and when the dosage is adjusted up or down, and instruct them to report such symptoms to the healthcare provider .

Important Administration Instructions

Instruct patients to swallow paroxetine extended-release tablets whole and to not chew or crush the tablets .

Serotonin Syndrome

Caution patients about the risk of serotonin syndrome, particularly with the concomitant use of paroxetine extended-release tablets with other serotonergic drugs including triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, St. John's Wort, and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid). Instruct patients to contact their health care provider or report to the emergency room if they experience signs or symptoms of serotonin syndrome . …

Warnings & precautions

Do not take this medicine if: Paroxetine extended-release tablets are contraindicated in patients:

Taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome .

Taking thioridazine because of risk of QT prolongation .

Taking pimozide because of risk of QT prolongation .

With known hypersensitivity (e.g., anaphylaxis, angioedema, Stevens-Johnson syndrome) to paroxetine or to any of the inactive ingredients in paroxetine extended-release tablets .

In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and 4,500 pediatric patients, the incidence of suicidal thoughts and behaviors in antidepressant-treated patients age 24 years and younger was greater than in placebo-treated patients. There was considerable variation in risk of suicidal thoughts and behaviors among drugs, but there was an increased risk identified in young patients for most drugs studied. There were differences in absolute risk of suicidal thoughts and behaviors across the different indications, with the highest incidence in patients with MDD. The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1,000 patients treated are provided in Table 2.

Age Range | Drug-Placebo Difference in Number of Patients of Suicidal Thoughts and Behaviors per 1,000 Patients Treated

Increases Compared to Placebo

< 18 years old | 14 additional patients

18 to 24 years old | 5 additional patients

Decreases Compared to Placebo

25 to 64 years old | 1 fewer patient

≥ 65 years old | 6 fewer patients

It is unknown whether the risk of suicidal thoughts and behaviors in children, adolescents, and young adults extends to longer-term use, i.e., beyond four months. …

Paroxetine side effects

The following adverse reactions are included in more detail in other sections of the prescribing information:

Hypersensitivity reactions to paroxetine

Suicidal Thoughts and Behaviors

Serotonin Syndrome

Embryofetal Toxicity

Increased Risk of Bleeding

Activation of Mania/Hypomania

Discontinuation Syndrome

Seizures

Angle-closure Glaucoma

Hyponatremia

Bone Fracture

Sexual Dysfunction

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Safety data for paroxetine extended-release tablets is from 11 short-term, placebo-controlled clinical trials including 3 studies in patients with major depressive disorder (MDD) (Studies 1, 2, and 3), 3 studies in patients with panic disorder (PD) (Studies 4, 5, and 6), 1 study in patients with social anxiety disorder (SAD) (Study 7), and 4 studies in female patients with premenstrual dysphoric disorder (PMDD) (Studies 8, 9, 10, and 11) . These 11 trials included 1,627 patients treated with paroxetine extended-release tablets.

Studies 1 and 2 were 12-week studies that enrolled patients 18 to 65 years old who received paroxetine extended-release tablets at doses ranging from 25 mg to 62.5 mg once daily. …

Drug interactions

Table 6 includes clinically significant drug interactions with paroxetine extended-release tablets.

Monoamine Oxidase Inhibitors (MAOIs)

Clinical Impact | The concomitant use of SSRIs, including paroxetine extended-release tablets, and MAOIs increases the risk of serotonin syndrome.

Intervention | Paroxetine extended-release tablets are contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue .

Examples | selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue

Pimozide and Thioridazine

Clinical Impact | Increased plasma concentrations of pimozide and thioridazine, drugs with a narrow therapeutic index, may increase the risk of QTc prolongation and ventricular arrhythmias.

Intervention | Paroxetine extended-release tablets are contraindicated in patients taking pimozide or thioridazine .

Other Serotonergic Drugs

Clinical Impact | The concomitant use of serotonergic drugs with paroxetine extended-release tablets increases the risk of serotonin syndrome.

Intervention | Monitor patients for signs and symptoms of serotonin syndrome, particularly during treatment initiation and dosage increases. …

About this medicine

Paroxetine extended-release tablets, USP contain paroxetine hydrochloride, an SSRI. It is the hydrochloride salt of a phenylpiperidine compound identified chemically as (-)-trans-4R-(4'-fluorophenyl)-3S-[(3',4'methylenedioxyphenoxy) methyl] piperidine hydrochloride hemihydrate and has the empirical formula of C19H20FNO3∙HCl∙1/2H2O. The molecular weight is 374.8 g/mol (329.4 g/mol as free base). The structural formula of paroxetine hydrochloride is:

Paroxetine hydrochloride is an odorless, off-white powder, having a melting point range of 120°C to 138°C and a solubility of 5.4 mg/mL in water.

Paroxetine extended-release tablets, USP are intended for oral administration. Each extended-release tablet contains 12.5 mg, 25 mg, or 37.5 mg paroxetine equivalent to 14.25 mg, 28.51 mg, or 42.76 mg of paroxetine hydrochloride, respectively. One layer of the tablet consists of a degradable barrier layer and the other contains the active material in a hydrophilic matrix. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID f39a2a7a-7a7e-4dd8-9704-54d9598504fb. Read the full official label on DailyMed.

Related medicines

Sertraline Escitalopram Bupropion Fluoxetine Trazodone Duloxetine Prednisone Buspirone